Table 2 Major ongoing clinical trials of elotuzumab

NCT01335399 (ELOQUENT-1)

Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma

3

750

Active, not recruiting

NCT02272803

Phase II study of lenalidomide/dexamethasone with or without elotuzumab for newly diagnosed MM patients in Japan

2

80

Recruiting

NCT01241292

Japanese study of BMS-901608 (Elotuzumab) in combination with lenalidomide and low dose dexamethasone

1

7

Active, not recruiting

NCT02159365

Study of safety of elotuzumab administered over approximately 60 min in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients

2

76

Active, not recruiting

NCT01393964

Study of elotuzumab in combination with lenalidomide and dexamethasone in subjects with multiple myeloma and various levels of renal function

1

35

Active, not recruiting

NCT02279394

Trial of combination of elotuzumab and lenalidomide +/− dexamethasone in high-risk smoldering multiple myeloma

2

82

Recruiting

NCT02420860

Study of elotuzumab with lenalidomide as maintenance after autologous stem cell transplant (ASCT)

2

100

Recruiting

NCT02655458

Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide maintenance for multiple myeloma

1

15

Recruiting

NCT02612779

A study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd) in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide

2

60

Recruiting

NCT02654132

Trial of pomalidomide and low-dose dexamethasone with or without elotuzumab to treat refractory and relapsed and refractory multiple myeloma (ELOQUENT-3)

2

121

Recruiting

NCT01668719 (S1211)

Bortezomib, dexamethasone, and lenalidomide with or without elotuzumab in treating patients with newly diagnosed high-risk multiple myeloma

1/2

122

Recruiting

NCT02375555

Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly diagnosed MM

2

40

Recruiting

NCT02495922 (GMMG HD6)

A phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

3

516

Recruiting

NCT02718833

A study of elotuzumab with pomalidomide, bortezomib, and dexamethasone in relapsed multiple myeloma

2

46

Recruiting

NCT02726581

Study of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in multiple myeloma

3

406

Recruiting

NCT02252263

A phase I open label study of the safety and tolerability of elotuzumab (BMS-901608) administered in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) in subjects with multiple myeloma

1

136

Active, not recruiting